ASX stock of the day: Acrux (ASX:ACR) shares soar 36% on FDA approval

Acrux Limited (ASX: ACR) shares are soaring today after the pharma company gained a coveted FDA approval from the US government.

The Acrux Limited (ASX: ACR) share price is soaring today, up 36.36% at the time of writing to 22 cents a share.

Acrux shares closed at 16 cents a share yesterday but opened at 28 cents a share this morning before soaring all the way up to a high of 32 cents soon after. Even though Acrux has somewhat cooled off since, these new heights represent a 52-week high for the company.

So who is Acrux? And why are Acrux shares so convincingly on the march today?

An introduction

Acrux is a pharmaceutical company that describes itself as "dedicated to developing and commercialising topical pharmaceuticals". It was incorporated in 1998. Ever since, it has developed and commercialised a number of topically applied pharmaceutical products in the US and Europe.

Today, Acrux aims to develop a "range of topical and dermatological generic products for the US market". The company has three products approved for sale in the US, as well as a portfolio of topical products in development.

However, the company has had something of a rough trot over the past few years. Acrux no longer markets its flagship product Axiron (a testosterone replacement therapy) in the US after it lost patent protection. It withdrew it from sale back in 2017 due to competition from generic versions of this drug. It is still marketed outside the US, however. That is possibly why Acrux shares are, to this day, down 69% from the share price highs we saw back in 2016.

Even so, today Acrux has 14 generic products in its pipeline and has three products that have been submitted to the US Food and Drug Administration (FDA) for review. It also has an Evamist estradiol product, used in the treatment of menopause, available in the US market.

Why is the Acrux share price going gangbusters today?

Today's extraordinary performance in the Acrux share price can largely be attributed to a market release the company announced this morning just before open. In this release, Acrux informed investors that the FDA has approved a generic testosterone product. This product is based on Perrigo's Testosterone Topical Solution, which has a concentration of 30mg/1.5mL.

This news comes less than a week after Acrux announced the commencement of a new share purchase plan for existing retail shareholders. This plan was announced on 8 January and will run until 29 January. Shareholders can subscribe for up to $30,000 in new Acrux shares for a price of 15.7 cents a share.

But turning back to the FDA approval, the company had reportedly submitted an application for this product back in August 2018 that is a "generic equivalent" to the Perrigo product. Acrux is now able to manufacture and market this drug. The company was keen to point out that the Perrigo's product that Acrux's generic product mimics generated sales that "exceeded US$25 million" in the 12 months to September 2020.

Acrux had already entered into an exclusive sales, marketing and distribution agreement with another company – Dash Pharmaceuticals. Dash will apparently be responsible for "the commercialisation of the product in the United States". This will include the "coordination of commercial manufacturing and management of marketing and distribution".

Acrux CEO and managing director Michael Kotsanis had this to say on this news:

FDA approval is a major milestone for Acrux and its generic strategy. It is a testament to the hard work and dedication of the product development and regulatory team. We are excited to partner with Dash Pharmaceuticals to bring this product to market in the current financial year.

At the time of writing, the Acrux share price is sitting at 22 cents per share, giving the company a market capitalisation of $34.81 million.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »

Army man holding a drone while the army woman holds the remote control.
52-Week Lows

Can DroneShield shares rebound from fresh 52-week low, or is there more downside ahead?

Investors have fallen out of love with the counter-drone operator’s shares.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Frustrated man looking exhausted while sitting at his desk with his laptop and carrying his glasses in his hand.
ASX Share Market News

5 things to watch on the ASX 200 on Tuesday

It looks set to be a tough session for Aussie investors.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

Man with his hands out as if pondering his options.
Opinions

I've always loved Wesfarmers shares. But after a trip to Kmart, I'm not so sure

A weekend trip took some gloss off this stock.

Read more »